May New Deal Reads

New DealInflammatory bowel diseases, New Deal ReadsLeave a Comment

A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function. De Vries L. C. S et al.  Inflammatory Bowel Disease. 25 (4) 2019. Janus kinases (JAKs) are involved in the intestinal inflammation found in IBD. A common treatment for this disease is tofacitinib, a drug that inhibits different JAKs. Although this therapy is effective, it doesn’t target only … Read More

April New Deal Reads

New DealInflammatory bowel diseases, New Deal ReadsLeave a Comment

1. Targeting JAK-STAT signal transduction in IBD. Soendergaard C. et al. Pharmacology & Therapeutics 192(2018): 100-111 Antibody-based biological drugs were a significant advance for IBD treatments, but unfortunately a high percent of patients doesn’t respond well to this therapy highlighting the need for alternative therapies. Recent studies have shown the great potential of JAK inhibitors to face this unmet medical … Read More

February New Deal Reads

New DealInflammatory bowel diseases, New Deal ReadsLeave a Comment

In New Deal Reads we have prepared for you a selection of relevant papers in the field of IBD and nanotechnology so you can stay tuned with the new advances: 1. Local delivery of macromolecules to treat diseases associated with the colon, Bak A, .Ashford M, Brayden D.J. Journal: Advanced Drug Delivery Reviews in December 2018 The local delivery of … Read More